We are live on ! Find out more
B

Braidwell Portfolio holdings

AUM $3B
1-Year Est. Return 46.72%
This Fund
S&P 500
This Quarter Est. Return
+0.18%
1 Year Est. Return
+46.72%
3 Year Est. Return
+56.07%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3.03B
AUM Growth
+$47.9M
Cap. Flow
-$1.25B
Cap. Flow %
-41.28%
Top 10 Hldgs %
36.47%
Holding
100
New
13
Increased
18
Reduced
21
Closed
19

Top Buys

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$79.8M
2
DAWN
Day One Biopharmaceuticals
DAWN
+$37.4M
3
ENTA icon
Enanta Pharmaceuticals
ENTA
+$34M
4
HROW icon
Harrow
HROW
+$24.8M
5
IMCR icon
Immunocore
IMCR
+$24M

Top Sells

Rank Stock Value
1
NTRA icon
Natera
NTRA
+$30.7M
2
TVTX icon
Travere Therapeutics
TVTX
+$30.6M
3
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$26.8M
4
QDEL icon
QuidelOrtho
QDEL
+$25.7M
5
ACAD icon
Acadia Pharmaceuticals
ACAD
+$23.8M

Sector Composition

Rank Sector Weight
1 Healthcare 54.28%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GKOS icon
1
Glaukos
GKOS
$9.02B
$90.5M 2.99%
1,806,651
+144,800
+9% +$7.03M
ISEE
2
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$90.4M 2.98%
3,714,672
+373,372
+11% +$8.17M
NBIX icon
3
Neurocrine Biosciences
NBIX
$17.7B
$77.6M 2.56%
+766,800
New +$79.8M
XENE icon
4
Xenon Pharmaceuticals
XENE
$6.32B
$76.5M 2.52%
2,137,110
+589,000
+38% +$21.8M
ALGN icon
5
Align Technology
ALGN
$12B
$69.2M 2.28%
207,130
-12,800
-6% -$3.78M
BIIB icon
6
Biogen
BIIB
$29.9B
$61.4M 2.02%
220,742
-31,800
-13% -$8.8M
NVRO
7
DELISTED
NEVRO CORP.
NVRO
$59M 1.95%
1,632,915
+440,617
+37% +$15.5M
ISRG icon
8
Intuitive Surgical
ISRG
$121B
$57M 1.88%
223,120
– –
IRTC icon
9
iRhythm Holdings
IRTC
$3.59B
$56.3M 1.86%
454,169
-43,498
-9% -$4.72M
NTRA icon
10
Natera
NTRA
$37.5B
$54.5M 1.8%
982,241
-638,771
-39% -$30.7M
DCPH
11
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$50.1M 1.65%
3,241,351
-30,162
-0.9% -$504K
PCVX icon
12
Vaxcyte
PCVX
$7.89B
$49.5M 1.63%
1,319,978
-42,300
-3% -$1.79M
KIDS icon
13
OrthoPediatrics
KIDS
$485M
$44.2M 1.46%
998,871
-45,828
-4% -$2.03M
DAWN
14
DELISTED
Day One Biopharmaceuticals
DAWN
$42.2M 1.39%
3,159,895
+1,913,356
+153% +$37.4M
ENTA icon
15
Enanta Pharmaceuticals
ENTA
$372M
$42M 1.38%
1,038,310
+712,472
+219% +$34M
AMGN icon
16
Amgen
AMGN
$203B
$39M 1.29%
161,500
+30,400
+23% +$7.46M
CRNX icon
17
Crinetics Pharmaceuticals
CRNX
$8.86B
$32.4M 1.07%
2,019,714
-1,449,960
-42% -$26.8M
OM icon
18
Outset Medical
OM
$74.9M
$32.3M 1.06%
116,957
+3,320
+3% +$1.22M
HROW icon
19
Harrow
HROW
$1.43B
$30.7M 1.01%
+1,452,538
New +$24.8M
PEN icon
20
Penumbra
PEN
$12.5B
$29.8M 0.98%
107,044
-55,784
-34% -$14.2M
BLU
21
DELISTED
BELLUS Health Inc.
BLU
$29.7M 0.98%
4,126,194
+13,700
+0.3% +$106K
LEGN icon
22
Legend Biotech
LEGN
$4.3B
$29M 0.96%
601,801
-56,300
-9% -$2.75M
DICE
23
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
$28.2M 0.93%
984,800
+145,725
+17% +$4.32M
KRYS icon
24
Krystal Biotech
KRYS
$9.88B
$27.9M 0.92%
348,036
-10,020
-3% -$787K
MRUS
25
DELISTED
Merus
MRUS
$27.1M 0.89%
1,473,084
-525,000
-26% -$9.15M
1
2 3 4

Similar funds

NC
NZS Capital Denver, Colorado $3B AUM 21.29% 1-Year Est. Return
SGI
Swan Global Investments Durango, Colorado $3B AUM 15.66% 1-Year Est. Return
SP
SurgoCap Partners New York $2.99B AUM 39.34% 1-Year Est. Return
DIG
Dragoneer Investment Group San Francisco, California $3B AUM 6.95% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
VVP
Venture Visionary Partners Sylvania, Ohio $3B AUM 24.41% 1-Year Est. Return
ROTUOC
Regents of the University of California Oakland, California $3.01B AUM 11.91% 1-Year Est. Return
PHAM
Pacific Heights Asset Management San Francisco, California $2.99B AUM 52.5% 1-Year Est. Return

Braidwell's Q1 2023 Portfolio in Review

As of Q1 2023, Braidwell held 100 positions worth $3.03B, up 1.6% from $2.98B the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Braidwell withdrew a net $1.25B in Q1 2023, closing 19 positions and reducing 21 holdings. Its most notable exit was Travere Therapeutics, an estimated $30.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 54% of assets, down from 57% a quarter earlier.

Against the trend, Braidwell opened a new position in Neurocrine Biosciences worth $77.6M.

  • Braidwell's largest Q1 2023 buy was Neurocrine Biosciences: 766,800 shares worth $77.6M.
  • Braidwell added most to Day One Biopharmaceuticals in Q1 2023, an estimated $37.4M increase.
  • Braidwell's biggest Q1 2023 reduction was Natera, cutting an estimated $30.7M.
  • Braidwell fully exited Travere Therapeutics in Q1 2023, selling an estimated $30.6M.
  • Braidwell's ten largest holdings make up 36% of its $3.03B portfolio in Q1 2023.
  • Braidwell opened 13 new positions and closed 19 in Q1 2023.
  • Braidwell's portfolio value rose 1.6% quarter-over-quarter to $3.03B.

Based on Braidwell's 13F filing for Q1 2023, filed 15 May 2023.